CAMRF Quote, Financials, Valuation and Earnings

BioArctic AB has a net margin of 26.97% compared to Camurus AB's net margin of -25.62%. Camurus AB's return on equity of 11.41% beat BioArctic AB's return on equity of -23.03%.

Camurus AB has a consensus price target of --, signalling downside risk potential of --. On the other hand BioArctic AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Camurus AB has higher upside potential than BioArctic AB, analysts believe Camurus AB is more attractive than BioArctic AB.

Camurus AB has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioArctic AB has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Camurus AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioArctic AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Camurus AB pays -- of its earnings as a dividend. BioArctic AB pays out -- of its earnings as a dividend.

Camurus AB quarterly revenues are $46.2M, which are larger than BioArctic AB quarterly revenues of $7.4M. Camurus AB's net income of $12.5M is higher than BioArctic AB's net income of -$1.9M. Notably, Camurus AB's price-to-earnings ratio is 119.31x while BioArctic AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Camurus AB is 18.70x versus 107.08x for BioArctic AB. Usually stocks with elevated PS ratios are considered overvalued.

Hansa Biopharma AB has a net margin of 26.97% compared to Camurus AB's net margin of -213.29%. Camurus AB's return on equity of 11.41% beat Hansa Biopharma AB's return on equity of --.

Camurus AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Hansa Biopharma AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Camurus AB has higher upside potential than Hansa Biopharma AB, analysts believe Camurus AB is more attractive than Hansa Biopharma AB.

Camurus AB has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Hansa Biopharma AB has a beta of 0.486, suggesting its less volatile than the S&P 500 by 51.431%.

Camurus AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hansa Biopharma AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Camurus AB pays -- of its earnings as a dividend. Hansa Biopharma AB pays out -- of its earnings as a dividend.

Camurus AB quarterly revenues are $46.2M, which are larger than Hansa Biopharma AB quarterly revenues of $4.7M. Camurus AB's net income of $12.5M is higher than Hansa Biopharma AB's net income of -$10M. Notably, Camurus AB's price-to-earnings ratio is 119.31x while Hansa Biopharma AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Camurus AB is 18.70x versus 9.81x for Hansa Biopharma AB. Usually stocks with elevated PS ratios are considered overvalued.

Abliva AB has a net margin of 26.97% compared to Camurus AB's net margin of --. Camurus AB's return on equity of 11.41% beat Abliva AB's return on equity of --.

Camurus AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Abliva AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Camurus AB has higher upside potential than Abliva AB, analysts believe Camurus AB is more attractive than Abliva AB.

Camurus AB has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Abliva AB has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Camurus AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abliva AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Camurus AB pays -- of its earnings as a dividend. Abliva AB pays out -- of its earnings as a dividend.

Camurus AB quarterly revenues are $46.2M, which are larger than Abliva AB quarterly revenues of --. Camurus AB's net income of $12.5M is higher than Abliva AB's net income of -$1.9M. Notably, Camurus AB's price-to-earnings ratio is 119.31x while Abliva AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Camurus AB is 18.70x versus -- for Abliva AB. Usually stocks with elevated PS ratios are considered overvalued.

Oncopeptides AB has a net margin of 26.97% compared to Camurus AB's net margin of --. Camurus AB's return on equity of 11.41% beat Oncopeptides AB's return on equity of --.

Camurus AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Oncopeptides AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Camurus AB has higher upside potential than Oncopeptides AB, analysts believe Camurus AB is more attractive than Oncopeptides AB.

Camurus AB has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oncopeptides AB has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Camurus AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncopeptides AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Camurus AB pays -- of its earnings as a dividend. Oncopeptides AB pays out -- of its earnings as a dividend.

Camurus AB quarterly revenues are $46.2M, which are larger than Oncopeptides AB quarterly revenues of --. Camurus AB's net income of $12.5M is higher than Oncopeptides AB's net income of --. Notably, Camurus AB's price-to-earnings ratio is 119.31x while Oncopeptides AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Camurus AB is 18.70x versus 8.28x for Oncopeptides AB. Usually stocks with elevated PS ratios are considered overvalued.